PASADENA, Calif.--(BUSINESS WIRE)--July 19, 2006--Arrowhead Research Corporation (Nasdaq:ARWR - News), announced today that its majority-owned subsidiary, Insert Therapeutics, a company commercializing delivery-enhanced therapeutics using a patented class of polymeric systems, has treated its first patient in a Phase I study of IT-101, Insert's lead anti-cancer compound.
